Liet al.,Science 376 , eabi9591 (2022) 15 April 2022 5 of 13
Healthy Mild Moderate Severe
CD3
KIR
D
A
B
C
HC Mild
ModerateSevere
0
5
10
15
20
KIR
+/CD8
+ T cells (%)
***
****
****
**
without
vasculitis
with
vasculitis
0
2
4
6
8
CD25
hiCD127
lo/CD4
+^ T cells (%)
CD4+ Treg
without
vasculitis
with
vasculitis
0
20
40
60
80
100
KIR
+/NK cells (%)
KIR+ NK
HC Influenza-
infected
0
5
10
15
20
25
KI
+R
/CD
+ 8
T cells (%
)
KIR+ CD8
***
HC Influenza-
infected
0
1
2
3
4
5
CD2
hi 5
CD12
lo 7
/CD4
+ T cells (%)
CD4+ Treg
HC
ModerateSevere
0
5
10
15
KIR
+/CD8
+ T cells (%)
*
*
HC
COVID-19
0
5
10
15
KIR
+/CD
+ 8
T cells (%)
**
HC
COVID-19
0
5
10
15
20
KIR
+/CD8
+
T cells (%)
****
without
vasculitis
with
vasculitis
0
5
10
15
20
KI
+R
/CD8
+^ T
cells (%)
**
KIR+ CD8
Fig. 3. Increased KIR+CD8+T cells in infectious diseases.(A) Representa-
tive contour plots and summary scatter plots showing the percentage of
KIR+cells in CD8+T cells from the blood of 17 HCs and 53 COVID-19 patients
with varying disease severity (mild,N= 23; moderate,N= 17; severe,
N= 13). **P< 0.0001; Mann-Whitney test (left). P< 0.01; *P< 0.001;
**P< 0.0001; Kruskal-Wallis test followed by multiple comparisons test
(right). (B) Frequency of KIR+CD8+T cells, CD4+Tregs(CD25hiCD127lo), and
KIR+NK cells in the blood of COVID-19 patients with or without vasculitis.
**P< 0.01; Mann-Whitney test. (C) Frequency of CD8+T cells expressing
KIRtranscripts (KIR3DL1,KIR3DL2,KIR2DL3, orKIR2DL1) in the bronchoal-
veolar lavage fluid of HCs (N= 4) versus COVID-19 patients (N=9)(left;
**P< 0.01; Mann-Whitney test) and HCs versus COVID-19 patients with
moderate (N= 3) or severe (N= 6) disease (right; *P< 0.05; Kruskal-Wallis
test followed by multiple comparisons test). (D) Frequency of KIR+CD8+
T cells and CD4+Tregs(CD25hiCD127low) in the blood of HCs (N= 17) versus
influenza-infected patients (N= 7). ***P< 0.001; Mann-Whitney test.
RESEARCH | RESEARCH ARTICLE